Your browser doesn't support javascript.
loading
Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double-blinded placebo-controlled cross-over trial.
Golubic, Rajna; Hussein Ismail, Mouhamad; Josipovic, Masa; Kennet, Jane; Galderisi, Alfonso; Evans, Mark L.
Affiliation
  • Golubic R; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Hussein Ismail M; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
  • Josipovic M; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Kennet J; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Galderisi A; Department of Cell Biology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Evans ML; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Diabetes Obes Metab ; 25(10): 3059-3063, 2023 10.
Article in En | MEDLINE | ID: mdl-37312648
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Glucose Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Animals / Humans Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2023 Type: Article Affiliation country: United kingdom
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Glucose Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Animals / Humans Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2023 Type: Article Affiliation country: United kingdom